Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia
NYU Langone Health
Summary
The primary objective is to evaluate whether a single dose of psilocybin (25 mg), compared to placebo, can restore fronto-striatal reward circuit function and thereby improve anhedonia and emotional blunting in individuals with residual symptoms despite ongoing SSRI or SNRI treatment. This will be assessed using precision functional mapping (PFM), task-based fMRI, and clinical rating scales (DARS).
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age between 18 and 65 years * Able to provide voluntary signed and dated informed consent. * Females of childbearing potential (FOCBP) must agree to practice an effective means of birth control throughout the duration of the trial * Males who have FOCBPs as partners must agree to practice an effective means of birth control throughout the duration of the trial * State willingness to comply and be available for all study requirements, including psychological, cognitive, imaging and procedural evaluations for the duration of the study * Meet DSM-5 criteria for major depres…
Interventions
- DrugPsilocybin
One-time dose of psilocybin 25 mg, oral, in capsule form.
- DrugPlacebo
One-time dose of placebo (25 mg of inert filler), oral, in capsule form.
Location
- NYU Langone HealthNew York, New York